相关实验视频

Updated: Jun 4, 2025

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

在晚期清细胞细胞癌的免疫治疗中补充C3a的变化

Chen Zhang^1,2, Wenwen Yue², Weigang Bian^1,2

¹Department of Oncology, The First People's Hospital of Yancheng, Yancheng, China.

Translational andrology and urology

|December 19, 2024

概括

补充C3a在清细胞细胞癌 (CCRCC) 中高度表达,与瘤阶段和大小相关. 免疫治疗期间C3a水平的变化可以预测晚期CCRCC患者的治疗反应.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
生物化学生化学

背景情况:

清细胞细胞癌 (CCRCC) 越来越多地使用免疫疗法治疗.
补充C3a在CCRCC预后中的作用及其对免疫治疗结果的影响仍然不清楚.
了解C3a表达对于优化CCRCC治疗策略至关重要.

研究的目的:

调查补充C3a表达和早期CCRCC的临床病理特征之间的关联.
分析在晚期CCRCC免疫治疗期间补充C3a水平的变化.
确定C3a变化对治疗结果和患者存活时间的影响.

主要方法:

免疫组织化学被用来评估CCRCC瘤组织中的C3a表达.
在接受PD-1抑制剂免疫治疗前后的晚期CCRCC患者中,使用ELISA测量血清C3a度.
使用RECIST v1.1标准评估了治疗疗效.

主要成果:

在110例CCRCC中,补充C3a在69.09%的病例中得到表达,在较大的瘤 (>3.5厘米) 和晚期TNM阶段 (II阶段与II阶段) 中观察到更高的表达. 第一个阶段).
在接受免疫治疗的晚期CCRCC患者中,血清C3a水平在响应者 (CR/PR/SD) 中降低,在不响应者 (PD) 中增加.
治疗后C3a降低与明显更长的无进展生存时间相关 (P<0.001).

结论:

补充C3a在CCRCC中经常过度表达,其表达与瘤阶段和大小有关.
免疫治疗期间的血清C3a水平动态作为预测晚期CCRCC治疗反应的潜在生物标志物.
监测C3a变化可能有助于为CCRCC患者量身定制免疫治疗策略.

关键词:

清细胞细胞癌 (CCRCC) 是一种癌症.补充 C3a 的一个.免疫疗法免疫疗法编程细胞死亡蛋白1 (PD-1) 编程细胞死亡蛋白1

更多相关视频

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Evaluation of the Interplay Between the Complement Protein C1q and Hyaluronic Acid in Promoting Cell Adhesion

Evaluation of the Interplay Between the Complement Protein C1q and Hyaluronic Acid in Promoting Cell Adhesion

Published on: June 15, 2019

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...